-+ 0.00%
-+ 0.00%
-+ 0.00%

Baird Maintains Outperform on Alto Neuroscience, Lowers Price Target to $38

Benzinga·04/02/2026 17:58:10
Listen to the news
Baird analyst Brian Skorney maintains Alto Neuroscience (NYSE:ANRO) with a Outperform and lowers the price target from $41 to $38.